OVARIAN CANCER and US: population cancer screening

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label population cancer screening. Show all posts
Showing posts with label population cancer screening. Show all posts

Wednesday, July 21, 2010

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers



Conclusion: Our analysis suggested that among BRCA1/2 mutation carriers, prophylactic surgery would dominate or be cost effective compared to chemoprevention and screening. Annual screening with MRI and mammography was the most effective strategy because it was associated with the longest quality-adjusted survival, but it was also very expensive.

Sunday, July 04, 2010

HE4 and Mesothelin: Novel Biomarkers of Ovarian Cancer



"Addition of mesothelin to this combination did not show any improvement in the sensitivity. Conclusions: As a single marker, HE4 had the highest sensitivity for detecting ovarian carcinoma specially early stage disease. Combined CA125 and HE4 was a more accurate predictor of ovarian malignancy than either alone."

The Elusive Goal of Maintaining Population Cancer Screening: It Is Time for a New Paradigm -- Editorial (full free access)



Note: focus on breast cancer/not specific to ovarian cancer; discusses high risk (BRCA's) "In this issue of the Journal, Vernon et al. conducted a methodologically rigorous review of the literature on controlled behavioral interventions to increase repeat mammography screening among women at average risk for the disease.......The promise of breast cancer screening has fallen short of its goals because of its imprecision, failure to screen those at highest risk, lack of compliance with screening continuance over recommended periods of time, and gaps in access to or quality of diagnostic follow-up and treatment (20). It is no longer enough to simply conduct more interventions to understand which work best in motivating individuals to undergo repeat cancer screening. New paradigms, guided by evidence from modeling, novel trials, and new scientific discovery, will be needed to realize the promise of eliminating the burden of cancer."